On February 23rd, Sanofi announced that the US Food and Drug Administration (FDA) had granted dabitol& Reg; Priority review of the application for market authorization (sBLA) for the sixth potential indication of Duprizumab, which is used for additional maintenance therapy in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The FDA approval results are expected to be obtained on June 27, 2024.